Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-07-26
2011-07-26
Young, Shawquia (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S415000, C548S465000, C548S491000
Reexamination Certificate
active
07985763
ABSTRACT:
A compound of the following formula:in which R1, R2, R3, U, V, T, W, X, Y, Z, m, n, p, x, y, and z are as defined herein. Also disclosed are (1) a pharmaceutical composition containing such a compound, and (2) a method for treating Hepatitis C virus infection using such a compound.
REFERENCES:
patent: 3890348 (1975-06-01), Kathawala
patent: 4221817 (1980-09-01), Tenne
patent: 4413006 (1983-11-01), Kanno et al.
patent: 4574124 (1986-03-01), Kabbe et al.
patent: 5932742 (1999-08-01), Yoon et al.
patent: 6696487 (2004-02-01), Gerusz et al.
patent: 6706751 (2004-03-01), Aebi et al.
patent: 7094807 (2006-08-01), Chen et al.
patent: 7102007 (2006-09-01), Aebi et al.
patent: 2005/0020624 (2005-01-01), Aebi et al.
patent: 2005/0032849 (2005-02-01), Phadke et al.
patent: 2005/0228013 (2005-10-01), Thurkauf et al.
patent: 2006/0025416 (2006-02-01), Phadke et al.
patent: 2009/0264404 (2009-10-01), Yamashita et al.
patent: 2040438 (1971-03-01), None
patent: 2447378 (1979-01-01), None
patent: 1332008 (1973-10-01), None
patent: 2056968 (1981-03-01), None
patent: 2005330284 (2005-02-01), None
patent: 2005/144790 (2005-05-01), None
patent: WO 99/40088 (1999-08-01), None
patent: WO2004/046095 (2004-06-01), None
patent: WO2004/096210 (2004-11-01), None
patent: WO2005/095345 (2005-10-01), None
patent: WO2006/122011 (2006-11-01), None
Document No. 142:56122, retrieved from CAPLUS on Jan. 6, 2010.
Document No. 140:209908, retrieved from CAPLUS on Jan. 6, 2010.
Document No. 86:55235, retrieved from CAPLUS on Jan. 6, 2010.
Document No. 140:406359, retrieved from CAPLUS on Jan. 6, 2010.
Document No. 143:163157, retrieved from CAPLUS on Jan. 6, 2010.
Document No. 139:69296, retrieved from CAPLUS on Jan. 6, 2010.
Document No. 132:279477, retrieved from CAPLUS on Jan. 6, 2010.
Jefferson, et al., Bioorg. Med. Chem. Lett., 14, 2004, 5139-5143.
RN 500201-34-3 , entered in STN Mar. 21, 2003 retrieved from Registry.
Gugliamelli, Luis et al., Males de la Asociacion Quimica Argentina (1927), 15, pp. 337-362.
Arafa, Reem et al., J. Med. Chem. 2005, 48, 5480-5488.
Cory et al., “Use of an Aqueous Soluble Tetrazolium/Formazan Assay for Cell Growth Assays in Culture,”Cancer Communications, vol. 3, No. 7, (1991).
Honda et al., Chem. Abst. 135 357776 (2001).
Willson et al. Chem. Abst. 118: 212577 (1993).
Bennett et al., J. Am Chem Soc. 1953 75(23); 6039-6040.
Chao Yu-Sheng
Chern Jyh-Haur
Hsu Tsu-An
Kang Iou-Jiun
Lee Chung-Chi
National Health Research Institutes
Occhiuti Rohlicek & Tsao LLP
Young Shawquia
LandOfFree
Hepatitis C virus inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Hepatitis C virus inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hepatitis C virus inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2675696